Clinical Trials Logo

Acute Pulmonary Embolism clinical trials

View clinical trials related to Acute Pulmonary Embolism.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06189313 Not yet recruiting - Clinical trials for Cardiovascular Diseases

CLEANer Aspiration for Pulmonary Embolism

CLEAN-PE
Start date: May 23, 2024
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of the Cleanerâ„¢ Pro Thrombectomy System for aspiration thrombectomy in patients with acute pulmonary embolism (PE).

NCT ID: NCT05792397 Not yet recruiting - Clinical trials for Acute Pulmonary Embolism

TwiFlow Thrombectomy Catheter sYstem for Acute Pulmonary Embolism (Twi-TYPE Study)

Twi-TYPE
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

As a multicenter prospective single-arm clinical study, the investigators plan to recruit patients with acute pulmonary intravascular embolization from nationwide multi-center hospital organizations in China. The investigators use the production of transcatheter pulmonary artery bolt system which named 'TwiFlow Thrombectomy Catheter System' developed by the MorningSide (NanTong) medical device Co., LTD. on pulmonary artery interventional therapy to evaluating the efficacy and safety of this novel system in the treatment of patients with pulmonary intravascular embolization disease.

NCT ID: NCT05469724 Not yet recruiting - Clinical trials for Acute Pulmonary Embolism

Clinical Pulmonary Embolism

Start date: July 2022
Phase:
Study type: Observational

To evaluate the clinical characteristics, risk factors, management and outcome of patients admitted e acute pulmonary embolism in chest diseases department and Respiratory Icu in Assiut University hospital

NCT ID: NCT04480892 Not yet recruiting - Clinical trials for Acute Pulmonary Embolism

Fibrinolytic Deficit in Patients With Acute PE

Start date: August 2020
Phase:
Study type: Observational [Patient Registry]

Fibrinolysis is the body's process that prevents blood clots. The investigators hypothesize that patients presenting with acute pulmonary embolism (PE) or blood clots in the lungs differ in their fibrinolytic deficit phenotype. The investigators aim to use biomarkers directly involved in endogenous fibrinolytic cascade including PAI-1, Alpha-2-Antiplasmin (A2A), TAFI, D-dimer, and Fibrinogen to phenotypically characterize patients presenting with acute PE and to correlate these biomarkers with clinical, echocardiographic, computed tomography (CT), and functional status outcomes.

NCT ID: NCT04110275 Not yet recruiting - Clinical trials for Acute Pulmonary Embolism

Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)

rPA
Start date: October 2019
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to compare the efficacy and safety of Recombinant Human Tissue-Type Plasminogen Activator Derivative(rPA) and Recombinant Tissue-Type Plasminogen Activator(rt-PA) for the treatment of acute pulmonary embolism. This trial includes two stages, the first stage is to study the dosage of administration of the test drug(rPA), the second is to compare the efficacy and safety of rPA and rt-PA. Both of the two stages are randomized, open and parallel controlled.